VivoSeq
Nephrology

Kidney Stone

1

Pipeline Programs↗

6

Active Trials↗

4

Companies Involved↗

Kidney Stone is an early-stage landscape with 1 program across 4 companies. The most active players are Boehringer Ingelheim, Eli Lilly, Allena Pharmaceuticals. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

11/100

Mech. Concentration

100/100

Completion Rate

64/100

Attrition Rate

22/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3A

Allena Pharmaceuticals

0 programs

PreclinicalAlnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 31

Empagliflozin

Boehringer Ingelheim

Approved
No programs

Analysis

Trial Status

18

clinical trials

Completed7 · 39%
Recruiting5 · 28%
Withdrawn3 · 17%
Not yet recruiting1 · 6%
Unknown status1 · 6%
Terminated1 · 6%

Clinical Trials

Trial Activity

18 trials

Ear Pressure Points Plus Pain Meds for Faster Kidney Stone Pain Relief
Recruiting·—·N/A·NCT06978816·116 enrolled
Indapamide and Chlorthalidone to Reduce Urine Supersaturation for Kidney Stone Prevention
Recruiting·IInsel Gruppe AG, University Hospital Bern·Phase 2·NCT06111885·99 enrolled
Inflammation and Insulin Resistance in Kidney Stone Patients
Recruiting·UUniversity of Chicago·N/A·NCT06436235·40 enrolled
Randomized Placebo-controlled Trial to Assess Efficacies of EMPAgliflozin and Personalized Dietary Counselling for Kidney STONE Prevention in Patients With Calcium Kidney Stones Acronym: EMPASTONE Trial
Recruiting·IInsel Gruppe AG, University Hospital Bern·Phase 3·NCT06653738·400 enrolled
Randomized Controlled Trial of Miniaturized Percutaneous Nephrolithotomy With Vacuum-Assisted Access Sheaths Versus Conventional Sheaths for Treatment of Nephrolithiasis
Recruiting·TThe Cleveland Clinic·Preclinical·NCT05993546·90 enrolled
Role of Medication in Making Urine Less Acidic as Part of Kidney Stone Prevention
Not yet recruiting·UUniversity of Texas Southwestern Medical Center·Phase 1·NCT06819111·20 enrolled
Hydrochlorothiazide for Kidney Stone Recurrence Prevention
Completed·IInsel Gruppe AG, University Hospital Bern·Phase 3·NCT03057431·416 enrolled
Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria
Completed·AAllena Pharmaceuticals·Phase 2·NCT02289755·16 enrolled
Allopurinol Effect on MDA,NO,KIM-1 Urine Levels, RI and Renal Elastography in Kidney Stone Patients Post ESWL
Completed·SSanglah General Hospital·Phase 4·NCT05414669·35 enrolled
A Novel Approach for Reducing Hyperoxaluria and Kidney Stone Risk.
Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT06481150·18 enrolled
A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Kidney Stone Surgery (Percutaneous Nephrolithotomy [PCNL])
Completed·UUniversity of California, San Diego·Phase 4·NCT02384200·86 enrolled
Empiric Versus Selective Prevention Strategies for Kidney Stone Disease
Completed·VVanderbilt University Medical Center·Phase 4·NCT05365477·56 enrolled
Dietary Oxalate and Innate Immunity in Kidney Stone Disease
Completed·UUniversity of Alabama at Birmingham·Preclinical·NCT04051346·14 enrolled
A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels
Terminated·Alnylam Pharmaceuticals logoAlnylam Pharmaceuticals·Phase 2·NCT05161936·2 enrolled
The Effect of Vitamin D on Urinary Calcium Excretion in Kidney Stone Formers With High Urinary Calcium
Withdrawn·—·Phase 2/3·NCT00948740
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)